Programming - Hypertension Scientific Sessions

Christy Gliniak, PhD, presents during The Multifaceted Roles of Adipose Tissue at the American Heart Association's Hypertension Scientific Sessions 2022 at the Hilton San Diego Bayfront.Great programming begins with your accepted abstract!

Great science and new discoveries are at the heart of our scientific conferences.
See our Abstracts & Awards page for details about submitting your abstract to Hypertension Scientific Sessions 2023. Later in the summer, we will post scheduling details on this page.

About This Meeting

Hypertension 2023 Scientific Sessions, focusing on recent advances in basic and clinical research on hypertension, is considered the premier scientific meeting on the subject in the world. A collaborative effort between the Council on Hypertension and the Council on the Kidney in Cardiovascular Disease, the science submitted to this conference continues to bring us the most up to date developments on our understanding of: the causes of hypertension; its relationship to stroke, cardiac disease and kidney dysfunction; and the most effective means for detecting, evaluating and treating high blood pressure across diverse populations.

This year's programming also includes:

  • Recent Advances sessions
  • Clinical Science/Clinical Practice Track
  • Primary Care Track
  • Oral abstract sessions highlighting early career oral abstract presentations
  • Networking sessions
  • Trainee Advocacy Committee Poster session and competition
  • Award Lecture sessions 

Learning Objectives

  1. Discuss strategies to implement the 2017 Hypertension Clinical Practice Guidelines to prevent, detect, evaluate and manage hypertension and to meet the AHA/ACC Clinical Performance and Quality Measures for Adults with High Blood Pressure.
  2. Describe opportunities to improve blood pressure measurement in the clinical setting.
  3. Describe new research on methods to evaluate white coat and masked hypertension, and strategies to implement self-measured blood pressure monitoring.
  4. Describe current evidence-supported algorithms in evaluating and managing patients with resistant hypertension, as well as data on device-based interventions in resistant hypertension.
  5. Describe strategies to address clinical inertia, improve blood pressure control, while engaging patients in shared decision making, in an era of value-based reimbursement framework.
  6. Compare and contrast new developments from experimental hypertension research and implications for future therapeutics.